Other names: PIG8, TSP57, Translokin, KIAA0092 HGNC (Hugo): CEP57 Location: 11q21 DNA/RNA Description CEP57 spans over 42 kb and is composed of 11 exons.
Mutations

Germinal
Biallelic, loss-of-function mutations in CEP57 have been found in three MVA pedigrees (figure 3).
Implicated in
Mosaic variegated aneuploidy syndrome (MVA)
Note MVA is a rare recessive condition characterised by mosaic aneuploidies, predominantly trisomies and monosomies, involving multiple different chromosomes and tissues. Affected individuals typically present with severe intrauterine growth retardation and microcephaly. Eye anomalies, mild dysmorphism, variable developmental delay and a broad spectrum of additional congenital abnormalities and medical conditions may also occur. Prognosis The prognosis for an individual with MVA syndrome is based on the malformations present in the individual. There is early mortality in a significant proportion of cases due to failure to thrive and/or complications of congenital abnormalities, epilepsy, infections or malignancy. Cytogenetics MVA is characterised by mosaic aneuploidies, predominantly trisomies and monosomies, involving multiple different chromosomes and tissues. The proportion of aneuploid cells varies but is usually >10% and is substantially greater than in normal individuals. Some patients with MVA also demonstrate premature chromatid separation in colchicine-treated blood lymphocyte and fibroblast cultures. Oncogenesis The risk of malignancy in MVA is high with Wilms tumour, rhabdomyosarcoma, leukaemia and granulosa cell tumour of the ovary reported in several cases. Myelodysplastic syndrome has also been observed.
